POSTER ABSTRACT
Machine Learning-Guided Discovery of Drug Combinations Targeting PI3K and mTOR Pathways
Using Cell Culture and PDX Data CertisAI™ integrates high-throughput screening data with clinically relevant PDX models, helping drug developers design smarter, faster combinatorial strategies.
In this study, our ML identified promising PI3K-mTOR drug combinations across solid tumors and improved prediction accuracy with biomarker-informed retraining, highlighting combinations like Everolimus and Alpesib, now in clinical trials.
PRESENTATION
Preclinical Research in the Age of FDA Modernization and AI
Dive into the future of preclinical research with a focus on FDA Modernization and AI integration. This session covers how to enhance translational relevance by selecting human-relevant models based on genomic, phenotypic, and clinical alignment.
Learn how AI can guide model selection, predict drug response, and support regulatory-ready study design and biomarker strategies.
“The team at Certis hits the mark in all respects: excellent scientific execution, great communication, and a rare degree of flexibility. When I need to outsource preclinical studies, Certis will be my first choice every time.”
- Rick Russell, CEO, Tract Bio
Tumor MOdels Boston Resources
2024 AACR Poster
Evaluation of Autologous and Allogeneic T Cell-Based Therapies in Ex-Vivo and In-Vivo Xenograft Tumor Models
DownloadWebinar
Artificial Intelligence in Preclinical Research: Pathology, Biospecimens, and Model Selection
Watch On Demand
CLIA-Certified
AAALAC Accredited
OLAW Accredited
Your Translational Partner
Certis Oncology Solutions is an AI-enabled translational science company dedicated to realizing the promise of precision oncology. At the core of the company’s platform is CertisAI™, a patented machine-learning system designed to model the relationships between drug chemistry and tumor biology.
By integrating computational modeling with functional testing in clinically relevant patient-derived tumor models, Certis generates Oncology Intelligence®—highly predictive therapeutic response data that helps pharmaceutical companies select better drug candidates, design smarter development strategies, and improve the probability of clinical success.
